62 results
8-K
EX-10.1
MYMD
MyMD Pharmaceuticals Inc
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
opposite such Buyer’s name in column (4) on the Schedule of Buyers, substantially in the form attached hereto as Exhibit B (the “Long-Term Warrants … of Preferred Shares as is set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers along with Long-Term Warrants to initially acquire up
8-K
EX-10.2
MYMD
MyMD Pharmaceuticals Inc
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
Stock set forth opposite such Buyer’s name in column (4) on the Schedule of Buyers, substantially in the form attached hereto as Exhibit B (the “Long-Term Warrants … , with the Long-Term Warrants, the “Warrants”) (the shares issuable upon exercise of the Warrants, the “Warrant Shares”).
The parties hereto shall
8-K
MYMD
MyMD Pharmaceuticals Inc
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
of Common Stock (the “Series G Long-Term Warrants,” and collectively with the Series G Short-Term Warrants, the “Series G Warrants”) at an exercise … ”) at an exercise price of $1.816 per share, and (iii) warrants to acquire up to an aggregate of 1,183,921 shares of Common Stock (the “Series F-1 Long-Term Warrants
8-K
EX-10.5
MYMD
MyMD Pharmaceuticals Inc
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
will sell to the Investors $8,950,000 of Convertible Preferred Stock (“Preferred”) with Long-Term Warrants and Short-Term Warrants to purchase shares … , and similar events.
Long-Term Warrants:
100% coverage on the Preferred, shall have a five (5) year term with an exercise price equal to the Conversion Price
424B5
d5mi49l
17 Aug 22
Prospectus supplement for primary offering
3:00pm
8-K
EX-10.3
gmkaob3i
21 Apr 21
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
9:56pm